Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG INNOLET versus SEMGLEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG INNOLET versus SEMGLEE.
NOVOLOG INNOLET vs SEMGLEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
Long-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake (especially in skeletal muscle and fat) and inhibiting hepatic glucose production via binding to insulin receptors, activating the insulin receptor tyrosine kinase cascade.
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
Subcutaneous injection, 0.2 units/kg/day initially, adjusted based on blood glucose levels. Typical maintenance dose: 0.5-1 unit/kg/day.
None Documented
None Documented
Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination
18.3 hours; reflects protracted absorption from subcutaneous depot, enabling once-daily dosing
Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%)
Renal (30-80% as intact insulin); fecal (negligible)
Category C
Category C
Insulin Analog
Insulin Analog